Lenz Therapeutics, a San Diego biotech developing an eye drop to improve near vision, signed a licensing agreement with Taiwan-based Lotus worth up to $125 million.
Why it matters: The FDA is reviewing Lenz's lead candidate, LNZ100, with its decision expected in August.
